Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
AURA Quote, Financials, Valuation and Earnings
Last price:
$5.87
Seasonality move
:
-3.99%
Day range:
$5.72 - $5.92
52-week range:
$4.35 - $8.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.38x
Volume:
99.1K
Avg. volume:
188.5K
1-year change:
-30.2%
Market cap:
$372.8M
Revenue:
--
EPS (TTM):
-$1.93
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AURA
Aura Biosciences, Inc.
|
-- | -- | -- | -- | $19.40 |
|
FDMT
4D Molecular Therapeutics, Inc.
|
$5.3M | -$0.93 | 3085400% | -51.32% | $33.11 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AURA
Aura Biosciences, Inc.
|
$5.87 | $19.40 | $372.8M | -- | $0.00 | 0% | -- |
|
FDMT
4D Molecular Therapeutics, Inc.
|
$7.97 | $33.11 | $455.4M | -- | $0.00 | 0% | 3,546.51x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AURA
Aura Biosciences, Inc.
|
10.18% | 1.769 | 4.56% | 8.60x |
|
FDMT
4D Molecular Therapeutics, Inc.
|
5.69% | 4.681 | 5.48% | 8.22x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AURA
Aura Biosciences, Inc.
|
-$300K | -$27.9M | -60.63% | -67.74% | -- | -$20.2M |
|
FDMT
4D Molecular Therapeutics, Inc.
|
-$1.9M | -$61.2M | -42.83% | -45.02% | -67983.33% | -$46.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Aura Biosciences, Inc. vs. Competitors
-
Which has Higher Returns AURA or FDMT?
4D Molecular Therapeutics, Inc. has a net margin of -- compared to Aura Biosciences, Inc.'s net margin of -63195.56%. Aura Biosciences, Inc.'s return on equity of -67.74% beat 4D Molecular Therapeutics, Inc.'s return on equity of -45.02%.
Company Gross Margin Earnings Per Share Invested Capital AURAAura Biosciences, Inc.-- -$0.40 $174.4M FDMT4D Molecular Therapeutics, Inc.-2125.56% -$1.01 $391.2M -
What do Analysts Say About AURA or FDMT?
Aura Biosciences, Inc. has a consensus price target of $19.40, signalling upside risk potential of 230.49%. On the other hand 4D Molecular Therapeutics, Inc. has an analysts' consensus of $33.11 which suggests that it could grow by 315.45%. Given that 4D Molecular Therapeutics, Inc. has higher upside potential than Aura Biosciences, Inc., analysts believe 4D Molecular Therapeutics, Inc. is more attractive than Aura Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AURAAura Biosciences, Inc.5 0 0 FDMT4D Molecular Therapeutics, Inc.7 2 0 -
Is AURA or FDMT More Risky?
Aura Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison 4D Molecular Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AURA or FDMT?
Aura Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. 4D Molecular Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences, Inc. pays -- of its earnings as a dividend. 4D Molecular Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AURA or FDMT?
Aura Biosciences, Inc. quarterly revenues are --, which are smaller than 4D Molecular Therapeutics, Inc. quarterly revenues of $90K. Aura Biosciences, Inc.'s net income of -$26.1M is higher than 4D Molecular Therapeutics, Inc.'s net income of -$56.9M. Notably, Aura Biosciences, Inc.'s price-to-earnings ratio is -- while 4D Molecular Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences, Inc. is -- versus 3,546.51x for 4D Molecular Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AURAAura Biosciences, Inc.-- -- -- -$26.1M FDMT4D Molecular Therapeutics, Inc.3,546.51x -- $90K -$56.9M
-
Which has Higher Returns AURA or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Aura Biosciences, Inc.'s net margin of -255.85%. Aura Biosciences, Inc.'s return on equity of -67.74% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital AURAAura Biosciences, Inc.-- -$0.40 $174.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About AURA or NBY?
Aura Biosciences, Inc. has a consensus price target of $19.40, signalling upside risk potential of 230.49%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Aura Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aura Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AURAAura Biosciences, Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is AURA or NBY More Risky?
Aura Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock AURA or NBY?
Aura Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aura Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AURA or NBY?
Aura Biosciences, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aura Biosciences, Inc.'s net income of -$26.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aura Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences, Inc. is -- versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AURAAura Biosciences, Inc.-- -- -- -$26.1M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns AURA or OGEN?
Oragenics, Inc. has a net margin of -- compared to Aura Biosciences, Inc.'s net margin of --. Aura Biosciences, Inc.'s return on equity of -67.74% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital AURAAura Biosciences, Inc.-- -$0.40 $174.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About AURA or OGEN?
Aura Biosciences, Inc. has a consensus price target of $19.40, signalling upside risk potential of 230.49%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Aura Biosciences, Inc. has higher upside potential than Oragenics, Inc., analysts believe Aura Biosciences, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AURAAura Biosciences, Inc.5 0 0 OGENOragenics, Inc.1 0 0 -
Is AURA or OGEN More Risky?
Aura Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock AURA or OGEN?
Aura Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AURA or OGEN?
Aura Biosciences, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Aura Biosciences, Inc.'s net income of -$26.1M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Aura Biosciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AURAAura Biosciences, Inc.-- -- -- -$26.1M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns AURA or PTN?
Palatin Technologies has a net margin of -- compared to Aura Biosciences, Inc.'s net margin of --. Aura Biosciences, Inc.'s return on equity of -67.74% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AURAAura Biosciences, Inc.-- -$0.40 $174.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About AURA or PTN?
Aura Biosciences, Inc. has a consensus price target of $19.40, signalling upside risk potential of 230.49%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Aura Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Aura Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AURAAura Biosciences, Inc.5 0 0 PTNPalatin Technologies0 0 0 -
Is AURA or PTN More Risky?
Aura Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock AURA or PTN?
Aura Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AURA or PTN?
Aura Biosciences, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Aura Biosciences, Inc.'s net income of -$26.1M is higher than Palatin Technologies's net income of --. Notably, Aura Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AURAAura Biosciences, Inc.-- -- -- -$26.1M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns AURA or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Aura Biosciences, Inc.'s net margin of --. Aura Biosciences, Inc.'s return on equity of -67.74% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital AURAAura Biosciences, Inc.-- -$0.40 $174.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About AURA or TOVX?
Aura Biosciences, Inc. has a consensus price target of $19.40, signalling upside risk potential of 230.49%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Aura Biosciences, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Aura Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AURAAura Biosciences, Inc.5 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is AURA or TOVX More Risky?
Aura Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock AURA or TOVX?
Aura Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AURA or TOVX?
Aura Biosciences, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Aura Biosciences, Inc.'s net income of -$26.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Aura Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AURAAura Biosciences, Inc.-- -- -- -$26.1M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
